1. Home
  2. TRC vs VOGX Comparison

TRC vs VOGX Comparison

Compare TRC & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tejon Ranch Co

TRC

Tejon Ranch Co

SELL

Current Price

$17.11

Market Cap

433.4M

Sector

Finance

ML Signal

SELL

Logo Vogenx Inc Common Stock

VOGX

Vogenx Inc Common Stock

SELL

Current Price

$13.73

Market Cap

482.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TRC
VOGX
Founded
1843
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.4M
482.8M
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
TRC
VOGX
Price
$17.11
$13.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 123.5K
74.7K
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.22
N/A
Revenue
★ $37,830,000.00
N/A
Revenue This Year
$10.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$77.73
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$15.31
$12.61
52 Week High
$21.31
$38.41

Technical Indicators

Market Signals
Indicator
TRC
VOGX
Relative Strength Index (RSI) 52.72 34.76
Support Level $15.87 N/A
Resistance Level $19.78 $22.10
Average True Range (ATR) 0.53 2.39
MACD 0.02 -0.37
Stochastic Oscillator 47.50 11.02

Price Performance

Historical Comparison
TRC
VOGX

About TRC Tejon Ranch Co

Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.

About VOGX Vogenx Inc Common Stock

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Share on Social Networks: